Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Edwards Lifesciences (EW) to $96 from $95 and keeps an Overweight rating on the shares after the company hosted its annual investor conference. Edwards expects 8%-10% underlying sales growth in 2026, with the midpoint below Street of about 9.8%. In 2026 and beyond, the company continues to target average about 10% revenue growth and leveraged EPS growth, Wells adds.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $103 from $100 at BTIG
- Edwards Lifesciences: Strategic Initiatives and Promising Developments Drive Raised Price Target
- Edwards Lifesciences: A Strong Growth Opportunity in Medtech with Expanding Market Potential and Robust Product Portfolio
- Edwards Lifesciences backs FY25 EPS view $2.56-$2.62, consensus $2.59
- Edwards Lifesciences sees FY26 adjusted EPS $2.80-$2.95, consensus $2.86